Ireland· IE-PA-EU/1/23/1759/002
Tepkinly 48 mg solution for injection
A amivantamab product containing epcoritamab, registered in Ireland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 15 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Amivantamab is registered in 15 of 19 countries.
Countries holding a registration under ATC L01FX18 (amivantamab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Amivantamab · ATC L01FX18
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of amivantamab costs, country by country.
Normalised to the WHO defined daily dose (75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Amivantamab · price per daily dose (75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$335.64
The record
At a glance
HPRA (Ireland)- Active substance
- Epcoritamab
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Ireland (IE)
- ATC code
- L01FX18
- ATC class
- Amivantamab
- Defined daily dose
- 75 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/23/1759/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Amivantamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceTEPKINLY 48 mg, solution injectableABBVIE DEUTSCHLAND (ALLEMAGNE)
- NetherlandsTepkinly 48 mg oplossing voor injectieAbbVie Deutschland GmbH & Co. KG
- United StatesEPKINLYGenmab US, Inc.
- CanadaEPKINLYABBVIE CORPORATION
- SwitzerlandTepkinly 4 mg/0,8 ml, InjektionslösungAbbVie AG
- CzechiaTEPKINLYAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- SpainTEPKINLY 4 MG/0,8 ML SOLUCION INYECTABLEAbbvie Deutschland Gmbh & Co. Kg
- FinlandTepkinlyAbbVie Deutschland GmbH&Co.KG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Tepkinly
- Iceland · Tepkinly
- Liechtenstein · Tepkinly
- Norway · Tepkinly
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f83e8f50-a574-43f1-a64a-1c7282cc12fe GET /v1/drugs/f83e8f50-a574-43f1-a64a-1c7282cc12fe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"L01FX18"
],
"strength": null,
"pa_number": "EU/1/23/1759/002",
"substances": [
"Epcoritamab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "22/09/2023",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about amivantamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.